| Num | PTM | Disease | Cell Type | Type | PTM Site | PMID |
|---|
| 1 | Phosphorylation | Esophageal squamous cell carcinoma | | P | | 21932407 |
[Reference]: As shown in Table III high p-4E-BP1 was associated with significantly higher LR but not DR. The locoregional control was excellent (97.1%) in low p-4E-BP1 tumors |
|
| 2 | Phosphorylation | Osteogenic sarcoma/Osteosarcoma | | P | | 23879172 |
[Reference]: FIM-A treatment resulted in the inhibition of mTORC1 signaling as demonstrated by the decreased phosphorylation of p70S6K1 and 4E-BP1. Consistent with this finding, FIM-A significantly decreased the average tumor volume, nuclei staining of PCNA, and the number of intratumoral microvessels |
|
| 3 | Phosphorylation | Ameloblastoma | | P | | 22977662 |
[Reference]: he nuclear expression of p-mTOR, p-4E-BP1 and p-p70S6K was associated with biological behaviors (invasiveness) of ABs, and p-mTOR was an independent predictor of AB |
|
| 4 | Phosphorylation | Synovial sarcoma | | P | | 23861137 |
[Reference]: In this study, the Akt/mTOR pathway was activated and was associated with worse clinical and pathologic behavior in patients with synovial sarcoma |
|
| 5 | Phosphorylation | Breast cancer/tumor/carcinoma | | P | | 17200342 |
[Reference]: Interestingly, p-4EBP1 was mainly expressed in poorly differentiated tumors (P < 0.001) and correlated with tumor size (P < 0.001), presence of lymph node metastasis (P = 0.002), and locoregional recurrences (P = 0.002) |
|
| 6 | Phosphorylation | Hepatocellular carcinoma/Hepatocarcinoma/Hepatoma | | U | | 23934262 |
[Reference]: Both of the compounds decreased the phosphorylation levels of p70 ribosomal protein S6 kinase (S6K) and eIF4E binding protein 1 (4E-BP1), resulting in cancer cell cytotoxicity and apoptosis |
|
| 7 | Phosphorylation | Lung adenocarcinoma | | U | | 23934262 |
[Reference]: Both of the compounds decreased the phosphorylation levels of p70 ribosomal protein S6 kinase (S6K) and eIF4E binding protein 1 (4E-BP1), resulting in cancer cell cytotoxicity and apoptosis |
|
| 8 | Phosphorylation | Bladder cancer | tumor tissue | U | | 23273076 |
[Reference]: In addition, patients with tumor recurrence had lower proportions of tumors with high phos-S6 (50% vs 69%, P = .04) and phos-4EBP1 (51% vs 69%, P = .05). |
|
| 9 | Phosphorylation | Gastric cancer | | U | | 24030871 |
[Reference]: Phosphorylated mTOR and phosphorylated 4E-BP1 were expressed in 71.1% and 68.4% of the human GC tissues tested, respectively; significantly higher than the levels in para-cancerous tissues (50% and 57.9%) and normal tissues (44.6% and 29%). |
|
| 10 | Phosphorylation | Chronic myelogenous leukemia/Chronic myeloid leukemia | tumor tissue | U | | 23384908 |
[Reference]: The phosphorylation of mTOR, 4E-BP1 and p70S6K were significantly increased in CML bone marrow cells compared with that of normal control (70.6% vs 30.0%, 76.5% vs 40.0%, 73.5% vs 20.0%, respectively, P < 0.05) |
|
| 11 | Threonine Phosphorylation | Liver cancer | cell line | P | T37 | 23537100 |
[Reference]: CCI-779 inhibited the phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser240/244), and 4EBP1 (Thr37/46) in different grades and the expressions of p70S6K, S6, and 4EBP1. As a result, CCI-779 induced a dose-dependent decrease in cell proliferation, G1/S arrest and damage of cell shape |
|
| 12 | Threonine Phosphorylation | Ovarian cancer/carcinoma | | U | T37 | 21276607 |
[Reference]: Expression of activated mTOR in our study had no association with prognostic factors and survival of patients with ovarian cancer. In addition, the expression of p-mTOR was not correlated with that of p-4EBP1 although we used an antibody against phosphorylated 4EBP1 (Thr37/46). |
|
| 13 | Threonine Phosphorylation | Non-small cell lung cancer/carcinoma | cell lines | U | T37 | 16397245 |
[Reference]: Fibronectin also increased the phosphorylation 4E-BP1 (Thr37/46), another downstream target of mTOR, in a time-dependent and dose-dependent manner with maximal induction at 24 hours |
|
| 14 | Threonine Phosphorylation | Liver cancer | cell line | P | T46 | 23537100 |
[Reference]: CCI-779 inhibited the phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser240/244), and 4EBP1 (Thr37/46) in different grades and the expressions of p70S6K, S6, and 4EBP1. As a result, CCI-779 induced a dose-dependent decrease in cell proliferation, G1/S arrest and damage of cell shape |
|
| 15 | Threonine Phosphorylation | Non-small cell lung cancer/carcinoma | | P | T46 | 16397245 |
[Reference]: We found that fibronectin stimulated the phosphorylation of Akt, an upstream inducer of mTOR, and induced the phosphorylation of p70S6K1 and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), two downstream targets of mTOR in NSCLC cells (H1792 and H1838), whereas it inhibited the phosphatase and tensin homologue deleted on chromosome 10, a tumor suppressor protein that antagonizes the phosphatidylinositol 5-kinase/Akt signal. |
|
| 16 | Threonine Phosphorylation | Intrahepatic cholangiocarcinoma | | P | T70 | 22248270 |
[Reference]: n addition, p-4EBP1 phosphorylation at Thr 70 could be a useful prognostic biomarker for ICC patients |
|
| 17 | Threonine Phosphorylation | Acute myeloid leukaemia/Acute myelogenous leukemia | | P | T70 | 18056483 |
[Reference]: We have recently demonstrated that the mTOR/4E-BP1/p70S6K pathway is constitutively activated in AML cells but not in their normal counterpart. |
|
| 18 | Threonine Phosphorylation | Rhabdomyosarcoma | | P | T70 | 16790088 |
[Reference]: We now demonstrate that CCI-779 rapidly inhibits mTOR activity, as indicated by S6 reduction and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation in two xenograft models of RMS within 24 hours of treatment. |
|